Staged IOL implantation = happy patients

Article

By employing staged implantation of intraocular lenses (IOLs), surgeons can produce the best possible visual outcomes for each individual patient.

By employing staged implantation of intraocular lenses (IOLs), surgeons can produce the best possible visual outcomes for each individual patient, according to Richard Lindstrom from Minnesota, USA.

Dr Lindstrom conducted a case series in which 23 patients received a dual diffractive IOL combination (ReStor/ReStor; Alcon) and 29 patients were implanted with a diffractive/refractive IOL combination (ReStor/ReZoom; AMO), using the process of staged implantation.

It was discovered that patient satisfaction with distance vision improved from 74% with the dual diffractive IOLs to 96% with the diffractive/refractive combination. Satisfaction with near vision improved from 83% to 96% and willingness to recommend the procedure to others improved from 64% to 96%. Furthermore, subjects with the diffractive/refractive combination reported spectacle independence 94% of the time, compared with just 65% of the time for the subjects with the dual diffractive IOLs.

Dr Lindstrom believes that the staged process can provide the best possible visual outcomes and that combining two different types of refractive IOLs leads to high levels of spectacle independence and patient satisfaction.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.